Search
Protara Therapeutics Inc
TARAAdd to Watchlist
4.020USD
-0.020-0.50%
Close 07-23 16:00（ET）Quotes delayed by 15 min
221.32MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Protara Therapeutics Inc is 8.25, ranking 142 out of 386 in the Biotechnology & Medical Research industry. The average price target is 25.00, with a high of 30.00 and a low of 21.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
26.667
Target Price
+552.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Protara Therapeutics Inc
TARA
8
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Protara Therapeutics Inc's price target?
Analysts forecast that Protara Therapeutics Inc's price target is USD 25.00, with the highest forecast at USD 30.00 and the lowest forecast at USD 21.00.
How have Protara Therapeutics IncTARA's recent earnings per share performed?
The market expectation was USD -0.31, while Protara Therapeutics IncTARA's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.33.
What is the analyst rating for Protara Therapeutics Inc?
Based on the ratings of Protara Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.